Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1953 1
1957 4
1961 1
1963 1
1966 3
1967 2
1968 1
1969 2
1971 1
1972 1
1973 5
1975 2
1976 4
1977 2
1978 2
1980 2
1981 1
1982 4
1983 4
1984 3
1985 5
1986 3
1987 1
1988 4
1989 3
1990 4
1991 1
1992 2
1993 1
1995 2
1997 2
1998 1
1999 3
2000 8
2001 8
2004 1
2005 1
2006 3
2007 4
2008 2
2009 3
2010 2
2011 8
2012 6
2013 3
2014 6
2015 9
2016 3
2017 5
2018 6
2019 8
2020 11
2021 14
2022 10
2023 6
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles.
György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, Kittel A, Nagy G, Falus A, Buzás EI. György B, et al. Among authors: laszlo v. Cell Mol Life Sci. 2011 Aug;68(16):2667-88. doi: 10.1007/s00018-011-0689-3. Epub 2011 May 11. Cell Mol Life Sci. 2011. PMID: 21560073 Free PMC article. Review.
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, Díaz-Manera J, Laforêt P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T; ATB200-07 Study Group. Schoser B, et al. J Neurol. 2024 May;271(5):2810-2823. doi: 10.1007/s00415-024-12236-0. Epub 2024 Feb 28. J Neurol. 2024. PMID: 38418563 Free PMC article. Clinical Trial.
Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
Breitenecker K, Homolya M, Luca AC, Lang V, Trenk C, Petroczi G, Mohrherr J, Horvath J, Moritsch S, Haas L, Kurnaeva M, Eferl R, Stoiber D, Moriggl R, Bilban M, Obenauf AC, Ferran C, Dome B, Laszlo V, Győrffy B, Dezso K, Moldvay J, Casanova E, Moll HP. Breitenecker K, et al. Among authors: laszlo v. Sci Transl Med. 2021 Jul 7;13(601):eabc3911. doi: 10.1126/scitranslmed.abc3911. Sci Transl Med. 2021. PMID: 34233950 Free PMC article.
Current therapy of KRAS-mutant lung cancer.
Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, Klepetko W, Lang C, Dome B, Megyesfalvi Z. Ghimessy A, et al. Among authors: laszlo v. Cancer Metastasis Rev. 2020 Dec;39(4):1159-1177. doi: 10.1007/s10555-020-09903-9. Cancer Metastasis Rev. 2020. PMID: 32548736 Free PMC article. Review.
[Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
Radeczky P, Ghimessy Á, Berta J, László V, Hegedűs B, Rényi-Vámos F, Fillinger J, Megyesfalvi Z, Döme B. Radeczky P, et al. Among authors: laszlo v. Magy Onkol. 2020 Sep 23;64(3):231-244. Epub 2020 Aug 6. Magy Onkol. 2020. PMID: 33196710 Free article. Review. Hungarian.
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, Díaz-Manera J, Dimachkie MM, Kushlaf H, Mozaffar T, Roberts M, Schoser B, Hummel N, Kopiec A, Holdbrook F, Shohet S, Toscano A; PROPEL Study Group. Kishnani PS, et al. J Patient Rep Outcomes. 2024 Nov 13;8(1):132. doi: 10.1186/s41687-024-00805-w. J Patient Rep Outcomes. 2024. PMID: 39535661 Free PMC article. Clinical Trial.
Afatinib restrains K-RAS-driven lung tumorigenesis.
Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E. Moll HP, et al. Among authors: laszlo v. Sci Transl Med. 2018 Jun 20;10(446):eaao2301. doi: 10.1126/scitranslmed.aao2301. Sci Transl Med. 2018. PMID: 29925635 Free PMC article.
Lung cancer in never smokers.
Torok S, Hegedus B, Laszlo V, Hoda MA, Ghanim B, Berger W, Klepetko W, Dome B, Ostoros G. Torok S, et al. Among authors: laszlo v. Future Oncol. 2011 Oct;7(10):1195-211. doi: 10.2217/fon.11.100. Future Oncol. 2011. PMID: 21992731 Free article. Review.
[Hepatocarcinogenesis in human liver].
Nagy P, László V, Schaff Z. Nagy P, et al. Among authors: laszlo v. Magy Onkol. 2006;50(2):107-13. Epub 2006 Aug 4. Magy Onkol. 2006. PMID: 16888673 Free article. Review. Hungarian.
200 results